

Economic evaluation of test-and-treat and empirical treatment strategies in the eradication of *Helicobacter pylori* infection; A Markov model in an Iranian adult population

Alireza Mazdaki¹, Hesam Ghiasvand², Ali Sarabi Asiabar³, Seyran Naghdi⁴
Aidin Aryankhesal^{*5}

Received: 18 April 2015

Accepted: 15 September 2015

Published: 14 February 2016

Abstract

Background: *Helicobacter pylori* may cause many gastrointestinal problems in developing countries such as Iran. We aimed to analyze the cost- effectiveness and cost- utility of the test-and-treat and empirical treatment strategies in managing *Helicobacter pylori* infection.

Methods: This was a Markov based economic evaluation. Effectiveness was defined as the symptoms free numbers and QALYs in 100,000 hypothetical adults. The sensitivity analysis was based on Monte Carlo approach.

Results: In the test- and- treat strategy, if the serology is the first diagnostic test vs. histology, the cost per symptoms free number would be 291,736.1 Rials while the cost per QALYs would be 339,226.1 Rials. The cost per symptoms free number and cost per QALYs when the 13 C-UBT was used as the first diagnostic test vs. serology was 1,283,200 and 1,492,103 Rials, respectively. In the empirical strategy, if histology is used as the first diagnostic test vs. 13 CUBT, the cost per symptoms free numbers and cost per QALYs would be 793,234 and 955,698 Rials, respectively. If serology were used as the first diagnostic test vs. histology, the cost per symptoms free and QALYs would be 793,234 and 368941 Rials, respectively.

Conclusion: There was no significant and considerable dominancy between the alternatives and the diagnostic tests.

Keywords: Cost- Effectiveness Analysis, Cost- Utility Analysis, Gastric Acid Anti-Secretory Treatment, *Helicobacter Pylori* Infection.

Cite this article as: Mazdaki A, Ghiasvand H, Sarabi Asiabar A, Naghdi S, Aryankhesal A. Economic evaluation of test-and-treat and empirical treatment strategies in the eradication of *Helicobacter pylori* infection; A Markov model in an Iranian adult population. *Med J Islam Repub Iran* 2016 (14 February). Vol. 30:327.

Introduction

Helicobacter pylori infection has a worldwide prevalence and causes some serious damages to human health. The infection increases the probability of gastric and duodenal ulcers, Mucosa Associated Lym-

phoid Tissue (MALT), lymphoma and gastric cancer (1-3). The prevalence rate varies worldwide ranging from 40% in developed countries to 80% in developing countries (4). *Helicobacter pylori* infection occurs during childhood and may cause gastritis,

¹. MA in Public Administration, Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran. mazdakii@yahoo.com

². PhD Candidate of Health Economics, Research Center for Modeling in Health, Institute for Futures Studies in Health, Kerman University of Medical, Kerman, Iran. hesambs82@gmail.com

³. MA in Public Administration, Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran. sarabi.a@iums.ac.ir

⁴. MSc in Health Economics, Research Center for Social Determinants of Health, Institute for Futures Studies in Health, Kerman University, Kerman, Iran. seyran.naghdi@gmail.com

⁵. (**Corresponding author**) Associate Professor, Department of Health Services Management, School of Health Management and Information Sciences, & Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran. aryankhesal.a@iums.ac.ir

typically without symptoms (5). According to the global statistics, particularly the World Health Organization's, the global burden of diseases attributable to *H. pylori* infection, which consist of a wide range of digestive system diseases including gastritis, gastric cancer, gastrointestinal bleeding, gastric and duodenal ulcers and indigestion are growing; and evidence shows that gastric cancer is the second leading cause of human mortality (6,7). According to the Iranian statistics, the prevalence of *Helicobacter pylori* infection in the northern and southern Iran has been more than 80%, and a significant part of the infected population faced subsequent diseases such as duodenal ulcer and gastric cancer (8,9). In this regard, the lack of infection symptoms, especially through the childhood, is the main concern, which causes late start of the treatment process (10). Attributing the probability of getting the infection into the economic and social, genetic, ethnic and demographic factors is considered as another point of concern (11).

The national and international economic consequences of *Helicobacter pylori* are remarkable. One study showed the cost of illness per person per six-months for patients with gastro-esophageal reflux diseases (GERD) and dyspepsia alone was around PPP\$ 111(320,609 I.R. Rials) – PPP, purchasing power parity- and PPP\$ 120 (345,935 I.R. Rials), respectively in 18,180 residents of Tehran from May 2006 to December 2007(12). Also, the researchers in another study estimated the direct costs of disease for GERD, dyspepsia and their overlap to be PPP\$ 97.7 and PPP\$ 101.3, respectively. The indirect costs of diseases per patient was PPP\$ 13.7, PPP\$ 12.1, and PPP\$ 32.7, for GERD, dyspepsia and their overlap, respectively (13). There are different but considerable evidence about the economic burden of *Helicobacter pylori* infection in other countries. In Malaysia (2010), the cost of dyspepsia per 1,000 population per year was estimated at US\$ 14,816.1 and US\$ 59,282.2 in rural and urban populations, respectively (14). The to-

tal cost of peptic ulcer disease and gastro-esophageal disease was US\$ 424 million or US\$ 63 per adult. The share of direct cost is about 61% from the total cost (15).

Given the role and importance of timely and accurate diagnosis of infection in the treatment and control of digestive system diseases and disorders, the use of safe, accurate and optimal cost-effective diagnostic methods is of a great necessity. Diagnostic tests in two forms of invasive and noninvasive were introduced and used to diagnose *Helicobacter* infection. Invasive tests include the rapid urease test and histological examination of gastric mucosal tissue and cell culture. On the other hand, non-invasive tests include serology (such as immunoglobulin G and A; antibodies against cell surface antigens), carbon urea breath test and faecal antigen tests (16). In the meantime, the emphasis on invasive or noninvasive methods depends on some factors such as cost, accuracy and ease of use. Among the above mentioned diagnostic tests, carbon urea breath test, due to its non-invasive nature and ease of use, has been addressed in several studies and many issues have been raised about its application (5).

The high prevalence of *Helicobacter pylori* between Iranian population and the lack of decision-making evidence led us to conduct the current study. This study encompasses descriptive and analytical implications about the significance of effective management of *Helicobacter pylori* infection for Iranian health policy makers.

Given the significant importance of timely diagnosis of the mentioned infection and its impact on avoiding the imposition of significant costs on the health systems, this study aimed to measure and compare cost-effectiveness and cost-utility ratios of carbon 13 urea breath test, serology and histology among the Iranian adult population using Markov model.

Methods

Economic Evaluation Type: This was a cost- effectiveness and cost- utility analysis

that calculated and compared the cost per symptoms free cases and cost per QALYs for treatment regimens of *Helicobacter pylori* infection.

Type of Interventions: There are invasive and non-invasive diagnostic tests to detect the *Helicobacter pylori*. In addition, there are different therapeutic regimes to eradicate it. The diagnostic techniques are used as supplementary treatments for *Helicobacter pylori* infection as well. Hence, according to the literature (16-19), in this study, the economic evaluation compared strategies including both diagnostic and therapeutic methods.

We considered four therapeutic strategies for managing the *Helicobacter pylori*. The first three, called the test-and-treat regime are as follows: Proton Pump Inhibitor based triple treatment after infection detected by each of 13 CUBT, serology, and histology tests.

Study Population and Setting: We performed the calculations and comparisons on 100,000 hypothetical Iranian adult population with uninvestigated dyspepsia who had not used Non-Steroidal Anti-Inflammatory Drugs (NSAID) and had no symptoms of other diseases.

Dates and Sources of Data: The data on the effectiveness and quality of life were obtained from previous studies published during the recent 10 years. Data about costs were collected through a field study in Tehran from April 2014 to June 2014. Moreover, for sensitivity analysis, the cost data in Iran's health services fee schedule (2014) was used alongside the field study.

Modeling and Assumptions: A Markov model with a health services provider's perspective and one-year time horizon was used. The model encompassed two cycles: In the first cycle, to detect the probable infection, all those suspected to have *Helicobacter pylori* infection were asked to undergo one of the three diagnostic tests (13 CUBT, serology or histology). If the test result was negative, the participants went to the first branch of the model and got the gastric acid anti-secretory regimen. In this

regimen, each individual takes two pantoprazole 40 mg tablets per day for four weeks. After eight weeks, the individual is tested for *Helicobacter pylori* symptoms free status. If the symptoms are relieved, the individual reaches their mission state, but if the symptoms are not relieved, she/he falls in the recurrence state. All individuals in the recurrence state receive long-term medical supervision.

If the diagnostic test result was positive, the individual went on test-and-treat regime that contained a PPI based triple treatment. Here, the three diagnostic tests, with respect to their sensitivity and specificity and the number of patients were different in each treatment regimen. There are different numbers of detected patients with respect to the diagnostic test. Therefore, we faced three sub-strategies: (i) If 13 CUBT was used as the first diagnostic test, the sub-strategy would then be called UBT triple treatment; (ii) If serology was used as the first diagnostic test, the sub-strategy would then be called serology triple treatment; and (iii) if histology was the first diagnostic test, the sub-strategy would then be called histology triple treatment.

In this regimen, the patient takes two omeprazole 20 mg, four amoxicillin 500 mg and two clarithromycin 250 mg daily for four weeks. Also, 12 weeks after finishing the initial triple treatment, endoscopy was used to confirm the eradication, and symptoms-free state (remission state). Therefore, if the result was positive, the individual would be in the recurrence state and would need a long term care.

These strategies and the medications used to treat infection have been selected based on the international and national guidelines (20, 21) and availability of the drugs in the pharmacopoeia and pharmaceutical market in Iran. For example, according to the new guidelines, amoxicillin 1000 mg is one of the drugs used in triple therapy, but due to the lack of compliance with the conditions prescribed by physicians in the country, inevitably, its equivalent, two capsules of amoxicillin 500 mg were used. This was

Table 1. The Markov Model Assumptions

	Variables	Base case	95th Percentile	Distribution	References
1	H.pylori prevalence in Iran	0.8	0.8-0.93	Uniform	8, 9
2	Supposed population	100000	---	---	
3	Sensitivity of 13C-UBT	0.93	0.77- 0.981	Triangular	22- 24
4	Specificity of 13C-UBT	0.92	0.89- 0.951	Triangular	22- 24
5	Sensitivity of serology	0.88	0.8- 0.921	Triangular	16, 22 & 24
6	Specificity of serology	0.69	0.8- 0.929	Triangular	16, 22 & 24
7	Sensitivity of histology	0.7	0.93- 0.976	Triangular	22-24
8	Specificity of histology	0.9	0.85- 0.962	Triangular	22-24
9	The probability of symptoms- free in antisecretory strategy (during initial 4 weeks of treatment)	0.38	0.23 & 0.36	Beta	25- 27
10	The probability of symptoms- free in PPI based triple treatment(during initial 4 weeks of treatment)	0.77	0.61-0.0.85	Beta	28-30
	The probability of symptoms-free in quadruple treatment(during initial 4 weeks of treatment)	0.8	0.77-0.84	Beta	20
11	Probability of relapse at one year after antisecretory therapy	0.44	---	N/A	20
12	Probability of relapse at one year after eradication therapy	0.164	---	N/A	31, 32
13	The quality of life in antisecretory treatment strategy	0.834	0.86		33, 34
14	The quality of life in PPI based triple treatment strategy	0.83	---		34
15	Cost of UBT	840000*	37500-1658300	Gamma	---
16	Cost of Serology	179800	123200-224200	Gamma	---
17	Cost of Histology	2543100	684200-2551200	Gamma	---
18	Cost of Endoscopy	3550000	1350000-5000000	Gamma	
19	Cost of Antisecretory treatment regimen	1285000	1140000-1434000	Gamma	---
20	Cost of PPI based triple treatment regimen	2584250	2264350-2731750	Gamma	---

*Note: All costs currency is I.R. Iran Rials for April 2014 to June 2014.

the case for proton pump inhibitors. Although the derivatives of the two medicines, benzimidazole and imidazopyridine, are the main medicines as proton pump inhibitors in the global market, pantoprazole 40 mg and/or omeprazole 20 mg are used in Iran. The explanation of each strategy has been provided as follows:

The model assumptions have been presented in Table 1.

Outcomes

The main outcomes were as follows: The estimated symptoms-free cases, and quality adjusted life years (QALYs) at the end of two Markov cycles. The symptom-free cases were estimated through the multiplying the transition probabilities between the two

Markov cycles by supposed infected individuals entered to each Markov state. The QALYs were calculated through multiplying the weights of utility- extracted from relevant studies- by the number of individuals in each Markov state.

Costing: Although there is a market price for any resource utilized to diagnose and treat the *Helicobacter pylori*, many experts believe that the prices cannot reflect the real costs, Therefore, all related costs were calculated by the researchers independently. In this study, the activity-based costing method was used to estimate the cost of each diagnostic procedure and subsequently the cost of two treatment strategies. The data about performing the diagnostic tests have been collected through a field study in

two private laboratories in Tehran. The medicines price was obtained from Iranian Ministry of Health and Social Security Organization. This has been done through the following steps:

1. Identification of the building process and activities of each strategy: Two strategies have been considered for *Helicobacter pylori* infection management: The proton-pump inhibitor-based triple therapy, and the gastric acid anti- secretory therapy, each of which includes some processes and activities. As mentioned earlier, both strategies begin with invasive or non-invasive diagnostic tests and then the therapeutic phase is managed with respect to the positive or negative detection of *Helicobacter pylori* infection. If the result of the test is positive then the infected person pays appropriate visits to the doctor, consultations and medical procedures. The therapeutic plan includes physician's examination and consultations, prescribing the drugs and finally investigating the eradication of infection. This process needs four physician's visits as activities.

2. Classification of each activity according to the cost hierarchy: The output of the first step is called activity center. In this study, there are three main activity costing centers: Detection activities, therapeutic activities and follow-up activities. The 13 C-UBT, serology and histology are three routine tests performed in laboratory setting. 13 C-UBT is a simple and fast test (about 15- 40 minutes), usually done by a laboratory technician, but the results are interpreted by a specialist. However, the histology and serology tests are more time consuming and need more medical equipment. The therapeutic plan is the second important activity center that includes the PPI-based triple and anti- secretory regimen. The physician's examinations, consultations, and prescriptions are the main activities in this phase. The follow up phase is the final activity center that includes a physician's examination and a diagnostic test to confirm the eradication of the infection (usually a biopsy-based test).

3. Identification and accumulation of the total costs of each activity: Each activity has been broken down into two components of the consumed time, and motion or effort of production resource. The histology test in the diagnostic phase contains the consumption of a share of each resource. The Tissue Processor, Tissue Flat, light microscope, microtome and paraffin dispenser are the main equipment in the *Helicobacter pylori* infection detection, but they are used to perform many microbiological tests. In this case, we divided the allocated time to *Helicobacter pylori* infection detection to all the activity time of equipment during the past year. The cost of manpower has been calculated through the time that was allocated to *Helicobacter pylori* infection by histology. This includes the allocated time by technicians, administrative employees and pathologists. With respect to the annual wages or salaries paid to each of them and the number of *Helicobacter pylori* infection tests that are performed, the allocated times has been calculated and then the unit cost of the manpower was estimated. The space cost has been computed through multiplying the occupied area of histology test setting (the equipment and manpower) by the monetary value of a commercial unit in a central district in Tehran.

The consumed energy costs were calculated with respect to the activity time of the histology equipment and its proportion from the total time of activity in the past year. This principle has been performed for the cost of other *Helicobacter pylori* infection tests and the management phases.

4. Identification of the most appropriate cost drivers for each activity: As mentioned in the previous step, it is of great importance to allocate an appropriated measurement unit to each activity. When we use resource- based costing, one of the most important steps is to determine the amount of consumption of resources (manpower, equipment, space, energy, supplies and materials). For example, in the diagnostic phase, the technician and

Table 2. The Key Elements of Cost Calculation of Helicobacter Pylori Management

Costing Variable	Measuring Unit	Price	Considerations
Equipment	The consumed time for a Helicobacter pylori infection diagnosis	Market price	Including the purchasing, establishing and maintenance costs
Manpower	Allotted time	Self-reported income by provider	Including: laboratory technicians, pathologist / PhD graduated in laboratory sciences, general and special physicians
Administrative Costs	Allotted time	Self-reported income by provider	Including: Administrative staff
Durable Supplies and Materials	The proportion allotted to Helicobacter pylori diagnosis and treatment	Market price	Including: the Kit, alcohol, paraffin, formalin, blade...
Space	The proportion of space allotted to diagnostic equipment in laboratory and services provider in therapeutic phase	Self-reported by provider	This calculated based on price in a central district in Tehran.
The Computerized Systems	Time allocated to Helicobacter pylori infection tests interpretation and print.	Self-reported by provider	The hardware and software facilities
Other Costs	The type of resource	Self-reported by provider, Market price and official bills	The electricity, energy, tax and duties, housekeeping, consumable supplies, ...

physician's cost, is measured by the needed time to perform each test, or the energy cost is calculated through the KW per hour.

5. Calculation of the unit costs: As the final step, the unit cost of each of the resources is calculated through dividing the total cost to the total amount of the produced services. The histology unit cost was calculated through dividing the total costs related to manpower, equipment, material and supplies, space, administrative affairs etc., to the total accomplished tests.

Table 2 demonstrates the costing components of each diagnostic test. The resource used the market prices. Data were collected from the provider's self-reported costs and his/her bills and the Iranian Ministry of Health and Social Security Organization.

Sensitivity Analysis: To investigate the effects of the uncertainty of relevant input variables (the prevalence of *Helicobacter pylori* infection, the sensitivity and specificity of diagnostic tests, the probability transitions between health state, and the costs of diagnostic tests and therapeutics




Fig. 1. The Markov Model of Helicobacter Pylori Infection Therapeutic Strategies

Notes: H.p- : *Helicobacter pylori* infection Negative, Antisec. Treat: Gastric acid antisecretory treatment regimen, pHP_positive: The probability of *Helicobacter pylori* infection is positive by each of diagnostic test, H.P+ Triple Treat: *Helicobacter pylori* infection is positive and the triple treatment adopted to eradication, Sym. Remis.: Symptoms remission, Sym. Recur.: Symptoms Recurrence, pHP_pos._Antisec.: Probability of symptoms free after anti-secretory treatment, pHP_Pos._Triple Treat: Probability of symptoms relief after PPI based triple treatment.

regimens), a probabilistic sensitivity analysis was conducted. The probability distributions were specified for the mentioned variables, and the Monte Carlo simulation was performed for 1,000 iterate points. The cost-effectiveness plane was drawn for considered strategies.

It should be noted that all calculations of the costs, cost-effectiveness and cost-utility ratios as well as drawing the Markov model were done using Microsoft Excel 2010.

Results

The results of this study are demonstrated in two tables and five graphs. The other graphs on the cost per QALYs are presented in the appendix. Table 3 presents the

unit cost of each strategy. The histology based triple treatment regimen was the most expensive, and the serology based anti-secretory regimens was the least expensive (Table 3).

Table 4 displays the cost per symptoms free results. The results indicated that the PPI based triple treatment, when serology was the first diagnostic test, was at the lowest amount. This result was also true about the cost per QALY ratio as well. Also, in anti-secretory regimens, if serology were used as the first diagnostic test, the cost per symptoms free and cost per QALY would have been at the lowest amounts compared to other strategies.

Figure 2 shows the graphical results of

Table 3. Unit Costs of Each Helicobacter Pylori Diagnosis and Therapeutic Regimen

Unit Cost Variables	Cost Per Unit based on I.R.I Rials (US\$)
The 13 CUBT based Anti- secretory** regimens	1281000 (43* US\$)
The Serology based Anti- secretory regimens	672960 (23 US\$)
The Histology based Anti- secretory regimens	3853000 (130 US\$)
The 13CUBT based Triple treatment*** regimens	8829740 Rials (298 US\$)
The Serology based Triple treatment regimens	6748320 (228 US\$)
The histology based Triple treatment regimens	9278050 (313 US\$)

Notes: All calculations related to 2014 April, when the 1US\$ = 29650 I.R.I Rial. *The US\$ costs have been rounded. ** Antisecretory regimens: Two physicians examinations (according to Iranian physicians fees 2014)+ two Pantoprazole 40 mg tablets per day for four weeks (the pantoprazole 40 mg price was obtained from the Social Security Organization), *** Triple treatment regimens: Four physicians examinations + two Omeprazole 20 mg, 4 Amoxicillin 500 mg and 2 Clarithromycin 250 mg daily (4 weeks)+ Endoscopy (the endoscopy cost has been obtained from physicians fee schedule)

Table 4. The Incremental Cost-effectiveness and Cost-utility Ratios of Alternatives in Eradication of Helicobacter Pylori Infection

Strategies	Description	Incremental Cost ** (I.R.I. Rials)	Incremental Effectiveness	Incremental QALYs	Cost per Symptoms free (I.R.I. Rials)	Cost per QALYs Gained in Population Allotted to Each Regimens (I.R. I.Rials)
PPI based Triple Therapy	Histology as first diagnostic test					
	Serology as first diagnostic test	2.7	62582	45821	291736	339226
	13C-UBT as first diagnostic test	3.3	25749	22144	1283200	1492103
Antisecretory	13C-UBT as first diagnostic test					
	Histology as first diagnostic test	4	20521	17853	793234	955698
	Serology as first diagnostic test	4.4	25871	18629	368941	444512

Notes: *Comparators have been sorted based on the effectiveness -from the lowest to the highest. ** The figures should be multiplied by ($\times 10^{11}$). Also, all of them were rounded.

Table 2, indicating that in triple treatment regimen, serology based strategy has clear dominance to 13 CUBT strategy in both aspects of cost per symptoms free and cost per QALY. In addition, in Figure 2, in anti-secretory treatment regimen, the serology-based strategy was dominant to histology-based strategy.

Costs: The unit costs of each strategy including both diagnostic and therapeutic phases are displayed in Table 3.

Table 3: Unit Costs of Each *Helicobacter Pylori* Diagnosis and Therapeutic Regimen
Cost- effectiveness Results: The results

of the calculations of cost-effectiveness and cost-utility of the four mentioned strategies are provided in Table 4.

The cost-effectiveness plane of symptoms free cases are shown in Figure 2, and the information on the cost per QALYs is presented in the appendix.

Sensitivity Analysis: The results of the probabilistic sensitivity analysis through the Monte Carlo simulation are presented in cost-effectiveness planes in Figures 3 to 6, separately. The sensitivity analysis results for costs per QALYs are shown in the appendix.




Fig. 2. *Helicobacter pylori* Symptoms-Free of Alternative Strategies at the End of the Cycles




Fig. 3. The Scatter Plane of Symptoms-free Cases in Triple Treatment (13CUBT as first Diagnostic test vs. Serology)

The Monte Carlo simulation result has been presented in Figure 3.

The Scatter plane of symptoms- free cases in triple treatment strategy when serology was used as the first diagnostic test vs.

histology is shown in Figure 4.

The scatter plane of symptoms- free cases in anti-secretory treatment when histology was used as the first diagnostic test against UBT is presented in Figure 5.




Fig. 4. The Scatter Plane of Symptoms-Free Cases in Triple Treatment (Serology as the First Diagnostic Test vs. histology)




Fig. 5. The Scatter Plane of Symptoms-free Cases in Antisecretory Treatment (Histology as the First Diagnostic Test vs. UBT)




Fig. 6. The Scatter Plane of Symptoms-free in Antisecretory Treatment (Serology as the First Diagnostic Test against Histology)

Finally, the scatter planes of symptoms-free cases in antisecretory treatment when serology was used as the first diagnostic test against the serology is shown in Figure 6.

Discussion

Economic considerations are among the main dimensions when evaluating any health method or technology. With regards to the carbon-13 urea breath method, the results of this study showed that the unit cost is 1,939,740 Rials (US\$ 65.42). If this method is used as the first diagnostic method of *Helicobacter pylori* infection, its unit cost in the triple therapy strategy would be 8,829,740 Rials (US \$298) per patient, and in the gastric acid antisecretory therapy strategy- empirical strategy it equals to 1,281,000 Rials (US \$43) per patient. On the other hand, if the serology method is used as the first diagnostic method of *Helicobacter pylori* infection, its unit cost - all three types of immunoglobulin- equals to 197,430 Rials (US\$ 6.7); if the triple therapy is used for the patient, its unit cost equals to 6,748,320 (US\$ 228); and in the gastric acid antisecretory therapy strategy, its unit cost would be 672,960 Rials (US\$ 23). With regards to the histology method, its unit cost equals to 2,569,940 Rials (US\$ 86.7); and if this diagnostic method is used in the triple therapy strategy, its unit cost would be 9,278,050 Rials (US\$ 313); and in the gastric acid antisecretory therapy strategy, the unit cost equals to 3,853,000 Rials (US\$ 130).

The cost per symptoms- free cases when the 13 CUBT was used as the first diagnostic test against serology was 1,283,200 Rials per symptoms- free cases and 1,492,103 Rials cost per QALYs in triple treatment strategy. Furthermore, the cost per symptoms free cases when serology was used as the first diagnostic test against histology was 291,736 and 339,226 Rials cost per QALYs. In antisecretory strategy, when histology was used as the first diagnostic test against the UBT, the cost per symptoms free was 793,234 and 955,698 Rials

per QALYs. Finally, in this strategy, when serology was used as the first diagnostic histology test, the cost per symptoms- free cases was 368,947 Rials and 444,512 Rials per QALYs.

The sensitivity analysis through the Monte Carlo approach with 95% confidence interval on the main key outcome variables (the differences between costs, symptoms-free as the first outcome, QALYs, cost per symptoms- free and cost per QALYs) showed a consistency in our results. This was obvious about the triple treatment alternatives. In all of the strategies, the differences in costs and outcomes (symptoms free number or QALYs) had a relative smooth (linear) pattern. Nonetheless, a difference could be observed in antisecretory strategy when serology was used as the first diagnostic test against histology.

According to the calculations of the carbon-13 urea breath method, the high unit cost of the carbon-13 urea breath method, compared to the serology method, is nearly 10 times more expensive than the serology method. Moreover, the lack of significant difference in the effectiveness of the two methods (according to the literature review, the difference between the sensitivity of the carbon-13 urea breath method and the serology method was only 0.05) suggests no specific dominancy of the carbon-13 urea breath method over the serology method at high levels of the prevalence of the *Helicobacter pylori* infection. On the other hand, with regards to the histology method, the carbon-13 urea breath method has a comparative advantage in terms of the cost per symptoms- free and QALYs, particularly in the gastric acid antisecretory therapy strategy, owing to the low cost difference (the histology method is about 1.3 times more expensive than the carbon-13 urea breath method), and the approximate equality in the effectiveness of the two mentioned diagnostic methods.

Results of a study conducted in Canada reveals no superiority between the serology method and the carbon-13 urea breath method in terms of cost-effectiveness (19).

Although the carbon-13 urea breath is more expensive, it is remarkably effective and can reduce the endoscopy referral burden. However, in sum, under the conditions of assumed parameters in the decision making model adopted by researchers of the current study, the carbon-13 urea breath method seems to be more cost-effective than the serology method. In general, the study concluded that the serology method is more appealing for patients with uninvestigated dyspepsia and at a low risk level.

A study was also conducted in Spain which aimed to evaluate the economic aspects of the general strategies including test- and- treat and a treatment strategy without test (35). The authors concluded that overall, the treatment strategy was better than the test-treatment strategy in terms of cost-effectiveness. Furthermore, among the used test-treatment methods in the mentioned strategy, the serology-based method was the most cost-effective followed by the urease test and carbon-13 urea breath methods. In the meantime, the carbon-13 urea breath method was more cost-effective than the cell culture and histology methods.

In another study conducted in Canada, the researchers concluded that the test-treatment strategy based on carbon-13 urea breath method has been more cost-effective than the other alternatives including endoscopy and serology methods. While the diagnostic effectiveness of this test was more than the other two, it was the most expensive method, and applying it to detect *Helicobacter pylori* infection at the primary level should be based on its use as the optimal method of detection (36).

Conclusion

With respect to the existing prevalence of *Helicobacter pylori* infection in Iran, owing to the high price of the carbon-13 urea breath method, and lack of significant cost-effectiveness and cost utility superiority over the serology and histology, we recommend avoiding its application in large scale and for large population groups. However if prescribed, given the significant

safety and diagnostic effectiveness, carbon-13 urea breath method should be used only for specific age groups, particularly children, and its use for older age groups does not seem cost-effective. In case that the prevalence of the *Helicobacter pylori* infection in Iran increases to a threshold of 93%, the use of the carbon-13 urea breath method may be cost-effective.

Limitations of the Study

Lack of valid data extracted from the related studies about the probability of symptoms recurrence in antisecretory strategy and the quality of life gained in PPI based triple treatment strategy resulted in some restrictions in conducting the sensitivity analysis. Nevertheless, it seems that these two parameters did not have much effect on our main results. The gastric cancer was one the most important outcomes of *Helicobacter pylori* infection, but was not investigated in our study. Thus, we recommend an economic evaluation considering gastric cancer in the future studies.

Acknowledgement

The author would like to thank Dr. Shahriar Khaghani for his valuable comments.

Gamma

References

1. Correa P, Piazuelo MB. Natural history of *Helicobacter pylori* infection. Dig. Liver Dis 2008; 40(7):490–496.
2. Kandulski A, Selgrad M, Malfertheiner P. *Helicobacter pylori* infection: a clinical overview. Dig. Liver Dis 2008;40(8):619–626
3. Khaleghi S, Talebi-Taher M, Salimi E, Taghipour H, Nekozadeh SH. Accuracy of diagnostic tests for *Helicobacter pylori* infection, J Ardabil Univ Med Sci 2012;12(4):363-372.[In Persian].
4. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of *Helicobacter pylori* infection. Clin. Microbiol. Rev 2006;19(3):449-90.
5. Falsafi T, Valizadeh N, Sepehr S, Najafi M. Application of a stool antigen test to evaluate the incidence of *Helicobacter pylori* infection in children and adolescents from Tehran, Iran. Clin Diagn Lab Immunol 2005;12(9):1094-7.
6. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J.Clin. Epidemiol 2003;

56:1-9.

7. Crew KD, Neugut AI. Epidemiology of gastric cancer. *World J. Gastroenterol* 2006; 12: 354-362.

8. Malekzadeh R, Sotoudeh M, Derakhshan MH, Mikaeli J, Yazdanbod A, Merat S, et al. Prevalence of gastric precancerous lesions in Ardabil, a high incidence province for gastric adenocarcinoma in the northwest of Iran. *J Clin. Pathol* 2004;57(1):37-42.

9. Hosseini E, Poursina F, Van de Wiele T, Ghasemian Safaei H, Adibi P. *Helicobacter pylori* in Iran: A systematic review on the association of genotypes and gastro duodenal diseases. *J. Res. Med. Sci* 2012;17(3):280-292.

10. World Health Organization. *Helicobacter pylori*. URL: http://www.who.int/vaccine-research/documents/ Helicobacter_pylori /en/. (Accessed in: September 2012).

11. Chen HL, Chen MJ, Shih SC, Wang HY, Lin IT, Bair MJ. Socioeconomic status, personal habits, and prevalence of *Helicobacter pylori* infection in the inhabitants of Lanyu. *J. Formos Med Assoc* 2014;113(5):278-83.

12. Vahedi M, Moghimi Dehkordi B, Safaei A, Pourhoseingholi A, Habibi M, Pourhoseingholi MA, et al. Cost analysis of upper gastrointestinal disorders in Tehran province: A population-based study, 2005-2006. *J Kermanshah Univ Med Sci* 2012; 16(6).

13. Moghimi Dehkordi B, Vahedi M, Khoshkrood Mansoori B, Kasaeian A, Safaei A, Habibi M, et al. Economic burden of gastro-oesophageal reflux disease and dyspepsia: A community-based study. *Arab J Gastroenterol* 2011;12(2):86-9.

14. Mahadeva S, Yadav H, Everett SM, Goh KL. Economic impact of dyspepsia in rural and urban malaysia: a population-based study. *J NeurogastroenterolMoti* 2012;18(1):43-57.

15. Agréus L, Borgquist L. The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden. *Pharmacoeconomics* 2002;20(5):347-55.

16. Australian Government, The Secretary Medical Services Advisory Committee, Carbon-labelled urea breath tests for diagnosis of *Helicobacter pylori* infection, February/March 2006.

17. Holmes K, Fong JC, Jackson BR. Cost-effectiveness of six strategies for *Helicobacter pylori* diagnosis and management in uninvestigated dyspepsia assuming a high resource intensity practice pattern. *Health ServRes* 2010; 10:344.

18. Garcia- Altea S, Jovell AJ, Serra Perat M, Aymerich M. Management of *Helicobacter pylori* in duodenal ulcer: a cost-effectiveness analysis. *Aliment PharmacolTher* 2000;14: 1631-1638.

19. Makris N, Barkun A, Crott R, Fallone C A. Cost-effectiveness of alternative approaches in the management of dyspepsia. *Int JTechnolAssess Journal* 2003;19(3):446-464.

20. Chey WD, Wong BCY. American College of

Gastroenterology Guideline on the Management of *Helicobacter pylori* Infection. *Am J Gastroenterol* 2007; 102:1808-1825.

21. Iranian Digestive Diseases Research Center (DDRC) Clinical Guideline on the Management of *Helicobacter pylori* Infection. Tehran University of Medical Sciences. Tehran, Iran, 2014.

22. Tian XY, Zhu H, Zhao J, Zhang GX. Diagnostic performance of Urea Breath Test, Rapid Urea Test, and Histology for *Helicobacter pylori* Infection in Patients with Partial Gastrectomy A Meta-analysis, *J Clin Gastroenterol* 2012;46:285-292.

23. Ling D. Carbon-13 urea breath test for *Helicobacter pylori* infection in patients with uninvestigated ulcer-like dyspepsia: an evidence-based analysis. *Ont Health Technol Assessment Series [Internet]* 2013 October;13(19):1-30.

24. Gisbert JP, Abaira V. Accuracy of *Helicobacter pylori* diagnostic tests in patients with bleeding peptic ulcer: A systematic review and meta-analysis, *Am J Gastroenterol* 2006;101:848-863.

25. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs triple therapy for primary treatment of *Helicobacter pylori* infection: systematic review and meta-analysis of efficacy and tolerability. *American Journal of Gastroenterology* 2010;105(1):65-73.

26. Moayyedi F, Feltbower R, Corcombe W, Manson S, Atha P, Brown J, et al. The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating *Helicobacter pylori* in a community screen and treat programme. *Aliment Pharmacol-Ther* 2000;14:719-728.

27. Chiba N, Veldhuyzen van Zanten SJO, Sinclair P, Ferguson RA, Escobedo S. Treating *Helicobacter pylori* infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment—*Helicobacter pylori* positive (CADET-Hp) randomised controlled trial, *BMJ* 2002;324:2.

28. Talley NJ, Lam SK, Goh KL, Fock KM. Management guidelines for uninvestigated and functional dyspepsia in the Asia-Pacific region: First Asian Pacific Working Party on Functional Dyspepsia. *J Gastroenterol Hepatol* 1998;13:335-353.

29. Wong WM, Gu Q, Lam SK, Fung FM, Lai KC, Hu WH, et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 2003;17(4):553-560.

30. Peura DA, Gudmundson J, Siepmann N, Pilmer BL, Freston J. Proton pump inhibitors: effective first-line treatment for management of dyspepsia. *Dig Dis Sci* 2007;52:983-987.

31. Kim MS, Kim N, Kim SU, Jo HJ, Shin CM, Park YS, et al. Long-term follow up *Helicobacter pylori* reinfection rate after second-line treatment:

bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy. *BMCGastroenterol* 2013, 13:138.

32. Georgopoulos SD, Ladas SD, Karatapanis S, Mentis A, Spiliadi C, Artikis V, Raptis SA. Factors that may affect treatment outcome of triple *Helicobacter pylori* eradication therapy with omeprazole, amoxicillin and clarithromycin. *Dig Dis Sci* 2000; 45(1):63-67.

33. Suzuki H, Okada S, Hibi T. Proton-pump inhibitors for the treatment of functional dyspepsia. *Ther Adv Gastroenterol* 2011;4(4):219-226.

34. Delaney B, Moayyedi P, Logan RFA, Ford

AC, Elliott C, McNulty C, et al. *Helicobacter pylori* test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicenter randomised controlled trial (MRC-CUBE trial). *BMJ* 2008;336(7645):651-4.

35. Genea E, Calvet X, Azagra A. Diagnosis of *Helicobacter pylori* after triple therapy in uncomplicated duodenal ulcers a cost-effectiveness analysis, *Aliment Pharmacol Ther* 2000;14:433-442.

36. Marshall JK, Armstrong D, O'Brien J. Test and treat strategies for *Helicobacter pylori* in uninvestigated dyspepsia: A Canadian economic analysis, *CanJ Gastrointestinal* 2000;14(5):379- 388.

Appendix



Fig. 1. *Helicobacter pylori* QALYs of the Alternative Strategies at the End of Cycles

Fig. 2. The Scatter Plane of QALYs in Triple Treatment (13CUBT as the first Diagnostic Test against Serology)




Figure 3: The Scatter Plane of QALYs in Triple Treatment (serology as the first Diagnostic test vs. Histology)




Fig. 4. The Scatter Plane of QALYs in Antisecretory Treatment (histology as first diagnostic test vs. UBT)




Fig. 5. The Scatter Plane of QALYs in Antisecretory Treatment (serology as first diagnostic test vs. histology)